Patents by Inventor Xun GUI

Xun GUI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LILRB4 antibodies and uses thereof
    Patent number: 12202895
    Abstract: The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: January 21, 2025
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, IMMUNE-ONC THERAPEUTICS, INC.
    Inventors: Zhiqiang An, Chengcheng Zhang, Ningyan Zhang, Xun Gui, Mi Deng, Tao Huang, Qiang Liu, X. Charlene Liao
  • Methods for identifying LILRB-blocking antibodies
    Patent number: 11906519
    Abstract: Provided herein are methods and compositions for the identification of modulators of ApoE-induced LILRB activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor of ApoE-induced LILRB activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of ApoE-induced LILRB activation to a subject.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: February 20, 2024
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Chengcheng Zhang, Zhiqiang An, Ningyan Zhang, Mi Deng, Jaehyup Kim, Xun Gui
  • Anti-LILRB antibodies and their use in detecting and treating cancer
    Patent number: 11498963
    Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: November 15, 2022
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Chengcheng Zhang, Mi Deng, Wei Xiong, Zhiqiang An, Ningyan Zhang, Xun Gui, Junke Zheng
  • Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer
    Patent number: 11377491
    Abstract: The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: July 5, 2022
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: X. Charlene Liao, Qiang Liu, Zhiqiang An, Ningyan Zhang, Xun Gui, Chengcheng Zhang, Mi Deng, Jingjing Xie
  • NOVEL LILRB4 ANTIBODIES AND USES THEREOF
    Publication number: 20210371518
    Abstract: The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.
    Type: Application
    Filed: September 12, 2019
    Publication date: December 2, 2021
    Inventors: Zhiqiang AN, Chengcheng ZHANG, Ningyan ZHANG, Xun GUI, Mi DENG, Tao HUANG, Qiang LIU, X. Charlene LIAO
  • METHODS FOR IDENTIFYING LILRB-BLOCKING ANTIBODIES
    Publication number: 20210349096
    Abstract: Provided herein are methods and compositions for the identification of modulators of ApoE-induced LILRB activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor of ApoE-induced LILRB activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of ApoE-induced LILRB activation to a subject.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 11, 2021
    Inventors: Chengcheng ZHANG, Zhiqiang AN, Ningyan ZHANG, Mi DENG, Jaehyup KIM, Xun GUI
  • TARGETING LILRB4 WITH CAR-T OR CAR-NK CELLS IN THE TREATMENT OF CANCER
    Publication number: 20210179687
    Abstract: The present disclosure provides methods and compositions for immunotherapy employing a modified T cell or NK cell comprising a chimeric LILRB4 antigen receptor (CAR) that can be administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: November 6, 2018
    Publication date: June 17, 2021
    Inventors: Chengcheng ZHANG, Samuel JOHN, Heyu CHEN, Mi DENG, Xun GUI, Ningyan ZHANG, Zhiqiang AN
  • ANTI-LILRB ANTIBODIES AND THEIR USE IN DETECTING AND TREATING CANCER
    Publication number: 20200079851
    Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.
    Type: Application
    Filed: November 8, 2019
    Publication date: March 12, 2020
    Inventors: Chengcheng ZHANG, Mi DENG, Wei XIONG, Zhiqiang AN, Ningyan ZHANG, Xun GUI, Junke ZHENG
  • Anti-LILRB antibodies and their use in detecting and treating cancer
    Patent number: 10501538
    Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: December 10, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Chengcheng Zhang, Mi Deng, Wei Xiong, Zhiqiang An, Ningyan Zhang, Xun Gui, Junke Zheng
  • ANTI-LAIR1 ANTIBODIES AND THEIR USES
    Publication number: 20190338026
    Abstract: The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.
    Type: Application
    Filed: January 2, 2018
    Publication date: November 7, 2019
    Inventors: X. Charlene LIAO, Qiang LIU, Zhiqiang AN, Ningyan ZHANG, Xun GUI, Chengcheng ZHANG, Mi DENG, Jingjing XIE
  • ANTI-LILRB ANTIBODIES AND THEIR USE IN DETECTING AND TREATING CANCER
    Publication number: 20180086829
    Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.
    Type: Application
    Filed: September 6, 2017
    Publication date: March 29, 2018
    Inventors: Chengcheng ZHANG, Mi DENG, Wei XIONG, Zhiqiang AN, Ningyan ZHANG, Xun GUI, Junke ZHENG